Study the Effect of Interleukin36 Gamma and AMH in Iraqi Women with PCOS

Wafa R. AlFatlawi

Abstract


Polycystic ovary syndrome (PCOS) is one of the most common female endocrine disorders and affect approximately (5-10) % of women of reproductive age. Anti-Müllerian hormone (AMH) is a homodimeric glycoprotein, a member of the transforming growth factor-β superfamily, it is secreted exclusively from women by granulose cells of ovarian follicles and it is considered as the precise marker of follicle pool size. AMH has been shown to be a good surrogate marker for polycystic ovary syndrome (PCOS). Interleukins are considered as strong risk markers of inflammation. Interleukin-36 gamma (IL36) also known as interleukin-1 family member 9 (IL1F9) is a protein that in humans is encoded by the IL36G gene. Serum samples were collected on day 2 of the menstrual cycle. Serum IL36ɣ, FSH and LH concentration were measured by using ELISA. This study aimed to evaluate the association between IL36ɣ and AMH and study the relationship between obesity and AMH of women in the age of reproductive (25-35) yrs. This study included 28 infertile women with PCOS their husbands were apparently normal (hormones and seminal fluid analysis), their aged (25-35) years, and 20 healthy women aged (25-33) years as control. All control women & patients were from outpatients unit of Alkadumia teaching hospital at Baghdad and all the parameters were measured in Sigma Laboratory. Serum IL-36 ɣ elevated in PCOS patients mainly those with high AMH levels. This hormone increased in PCOS patients compared with control. There was a non-significant difference between patients and control to LH and FSH levels.

Keywords


AMH, PCOS, IL-36, FSH.

Full Text:

PDF

References


Cristescu C. and Neagu M., "Anti-Műllerian hormone a prognostic marker for metformin therapy efficiency in the treatment of women with infertility and polycystic ovary syndrome." Vol.15, 4, 2012.

HimabinduY., Sriharibabu KM "Determination of Anti-Müllerian hormone level in Polycystic Ovary Syndrome, Infertile, and Healthy Iraqi Women.," Vol. 24,3, 2013.

Shevell T, Malone FD and Vidaver J. , ", Assisted reproductive technology and pregnancy outcome.," Vol. 106,5, 2005.

Makar RS and Toth T., "The evaluation of infertility." vol. 117, 2002.

Himabindu M Sriharibabu, KK Gopinathan, "Anti-mullerian hormone and antral follicle count as predictors of ovarian response in assisted reproduction," Vol. 6,1, 2013.

Gelbaya TA, Majumder K, and Laing I, "The use of anti-Mu¨ llerian hormone and antral follicle count to predict the potential of oocytes and embryos," Vol. 150, 2010.

DeVet A, Laven JS, JS,and DeJong FH, , " Antimullerian hormone serum levels:aputative marker of ovarian aging.," Vol. 77, 2002.

Motta AB" The role of obesity in the development of polycystic ovary syndrome," Vol. 18, 17, 2012.

Jenny A VisseFrank H de Jong, Joop S E Laven1 and Axel P N Themmen, "Anti-Müllerian hormone: a new marker for ovarian function," Vol. 131, 2006.

Homburg R.and Crawford G., "The role of AMH in anovulation associated with PCOS: a hypothesis," Vol. 29, 2014.

Cook CL, Siow Y, Brenner AG and Fallat ME, "Relationship between serum mulerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women," Vol. 77,1, 2002.

Cassar S, Teede H., "Polycystic Ovary Syndrome and Anti-Müllerian Hormone: Role of insulin resistance, androgens, obesity and gonadotropins," Vol. 81,6, 2014.

Sopher AB. Laura D., "Anti-Mullerian hormone may be a useful adjunct in the diagnosis of polycystic ovary syndrome in nonobese adolescents," Vol. 27, 2014.

Carlsson IB, Scott JE, Visser JA, Ritvos O, Themnen AP, Hovatta O., "Anti-Mullerian hormone inhibits initiation of growth of human primordial ovarian follicles in vitro.,"Vol. 21, 2006.

La Marca A. and Volpe A., " Anti-Mullerian hormone in female reproduction: is measurement of circulating AMH a useful tool?," Vol. 64, 2006.

Sighinolfi G, Radi D, Argento C , " Anti-Mullerian hormone as a predictive marker in assisted reproductive technology (ART).," Vol. 16, 2009.

Pergola G., Maldera S., and Tartagni M, " Inhibitory effect of obesity on gonadotropin, estradiol, and inhibin B levels in fertile women.," Vol. 14,11, 2006.

PignyP. ,Merlen E., and Y., " Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest.," Vol. 88, 2003.

Piltonen T, Morin P., Koivunen R, and Perheentupa A." Serum anti-Mullerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome," Vol. 20, 2005.

Gresnigt S. and, Rösler B., "The IL-36 receptor pathway regulates Aspergillus fumigatus-induced Th1 and Th17 responses.," Vol. 43,2, 2013.

Vigne S., and Palme G. " IL-36R ligands are potent regulators of dendritic and T cells.," vol. 118, 2011.

Dinarello C., and Arend W., " IL-1 Family Nomenclature.," Vol. 11, 2010.

Foster AM, Baliwag J, and Chen CS, "IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin," Vol. 192, 12, 2014.

Freeman E, Gracia C, Sammel MD, Lin H, Lim LC. and Strauss JF, " Association of anti-Müllerian hormone levels with obesity in late reproductive age women.," Vol. 87, 2007.

Seifer D and MacLaughlin D,, " Müllerian inhibiting substance is an ovarian growth factor of emerging significance.," Vol. 88, 2007.

Simón C1, Mercader A, and Frances A., " Hormonal regulation of serum and endometrial IL-1 alpha,IL-1 beta and IL-1ra: IL-1 endometrial microenvironment of thehuman embryo at the apposition phase under physiological andsupraphysiological steroid level conditions.," Vol. 31, 1996.

Karagouni EE, Chryssikopoulos A, Mantzavinos T, Kanakas N and Dotsika EN., "Interleukin-1beta and interleukin-1alpha may affect the implantation rateof patients undergoing in vitro fertilization-embryo transfer.," Vol. 70, 1998.

Zheng P. ,Yifan S. ,Xiaolan L., Hongyu Z., Chunming L. and Shengming D., PLOS ONE J, ". Interleukin-6 Levels in Women with Polycystic Ovary Syndrome," Vol. 11, 2, 2016.




DOI: http://dx.doi.org/10.23851/mjs.v28i3.551

Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 Al-Mustansiriyah Journal of Science

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


Copyright (c) 2018 by Al-Mustansiriyah Journal of Science
ISSN: 1814-635X (Print), ISSN: 2521-3520 (online)